AGG Talks: Government Insight for Life Sciences Leaders Podcast Series

How Medicare Regulations Could Affect Access to Gender-Affirming Care: Implications for Life Sciences Companies

Arnall Golden Gregory LLP Season 2 Episode 3

In this episode, AGG Life Sciences co-chair Alan Minsk and Healthcare partner Andrew Tsui examine how the Centers for Medicare & Medicaid Services ("CMS") may apply the Medicare Conditions of Participation ("COPs") to emerging areas of healthcare, including gender-affirming care — and what those developments could mean for pharmaceutical companies and drug manufacturers.

They discuss how updates to COPs can impact operational requirements for healthcare providers and influence compliance considerations. Andrew also examines how these changes could ripple through payor markets, pharmaceutical coverage, and the broader regulatory framework affecting the life sciences industry.

With his experience as former litigation counsel at HHS’s Office of the General Counsel, CMS Division, Andrew shares strategies that life sciences leaders can implement to adapt to modern regulatory and compliance actions.